{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:52:08Z","timestamp":1793404328339,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,14]],"date-time":"2019-12-14T00:00:00Z","timestamp":1576281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,14]],"date-time":"2019-12-14T00:00:00Z","timestamp":1576281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s40257-019-00497-9","type":"journal-article","created":{"date-parts":[[2019,12,14]],"date-time":"2019-12-14T07:05:42Z","timestamp":1576307142000},"page":"149-156","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Rituximab: A Review in Pemphigus Vulgaris"],"prefix":"10.1007","volume":"21","author":[{"given":"James E.","family":"Frampton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,14]]},"reference":[{"key":"497_CR1","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.3389\/fimmu.2019.01418","volume":"10","author":"D Didona","year":"2019","unstructured":"Didona D, Maglie R, Eming R, et al. Pemphigus: current and future therapeutic strategies. Front Immunol. 2019;10:1418.","journal-title":"Front Immunol."},{"key":"497_CR2","doi-asserted-by":"publisher","first-page":"17026","DOI":"10.1038\/nrdp.2017.26","volume":"3","author":"M Kasperkiewicz","year":"2017","unstructured":"Kasperkiewicz M, Ellebrecht CT, Takahashi H, et al. Pemphigus. Nat Rev Dis Primers. 2017;3:17026.","journal-title":"Pemphigus. Nat Rev Dis Primers."},{"issue":"2 Suppl 1","key":"497_CR3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1590\/abd1806-4841.2019940206","volume":"94","author":"AM Porro","year":"2019","unstructured":"Porro AM, Filho GH, Santi CG. Consensus on the treatment of autoimmune bullous dermatoses: pemphigus vulgaris and pemphigus foliaceus\u2014Brazilian Society of Dermatology. An Bras Dermatol. 2019;94(2 Suppl 1):20\u201332.","journal-title":"An Bras Dermatol."},{"issue":"4","key":"497_CR4","doi-asserted-by":"publisher","first-page":"301","DOI":"10.4103\/ijd.IJD_152_17","volume":"63","author":"KC Kiran","year":"2018","unstructured":"Kiran KC, Madhukara J, Abraham A, et al. Cutaneous bacteriological profile in patients with pemphigus. Indian J Dermatol. 2018;63(4):301\u20132.","journal-title":"Indian J Dermatol."},{"key":"497_CR5","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.3389\/fimmu.2018.01190","volume":"9","author":"KT Amber","year":"2018","unstructured":"Amber KT, Valdebran N, Grando SA. Non-desmoglein antibodies in patients with pemphigus vulgaris. Front Immunol. 2018;9:1190.","journal-title":"Front Immunol."},{"key":"497_CR6","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3389\/fmed.2018.00218","volume":"5","author":"AA Sinha","year":"2018","unstructured":"Sinha AA, Sajda T. The evolving story of autoantibodies in pemphigus vulgaris: development of the \u201csuper compensation hypothesis\u201d. Front Med (Lausanne). 2018;5:218.","journal-title":"Front Med (Lausanne)."},{"key":"497_CR7","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2147\/TCRM.S142471","volume":"14","author":"K Kridin","year":"2018","unstructured":"Kridin K. Emerging treatment options for the management of pemphigus vulgaris. Ther Clin Risk Manag. 2018;14:757\u201378.","journal-title":"Ther Clin Risk Manag"},{"key":"497_CR8","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1111\/bjd.15930","volume":"177","author":"KE Harman","year":"2017","unstructured":"Harman KE, Brown D, Exton LS, et al. British Association of Dermatologists\u2019 guidelines for the management of pemphigus vulgaris 2017. Br J Dermatol. 2017;177:1170\u2013201.","journal-title":"Br J Dermatol"},{"key":"497_CR9","doi-asserted-by":"crossref","unstructured":"Hertl M, Jedlickova H, Karpati S, et al. Pemphigus. S2 Guideline for diagnosis and treatment\u2013guided by the European Dermatology Forum (EDF) incooperation with the European Academy of Dermatologyand Venereology (EADV). JEADV. 2015;29:405\u201314.","DOI":"10.1111\/jdv.12772"},{"issue":"6","key":"497_CR10","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1007\/s12325-016-0343-4","volume":"33","author":"M Cholera","year":"2016","unstructured":"Cholera M, Chainani-Wu N. Management of Pemphigus vulgaris. Adv Ther. 2016;33(6):910\u201358.","journal-title":"Adv Ther."},{"key":"497_CR11","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1007\/s40265-018-0976-5","volume":"78","author":"KT Amber","year":"2018","unstructured":"Amber KT, Maglie R, Solimani F, et al. Targeted therapies for autoimmune bullous diseases: current status. Drugs. 2018;78:1527\u201348.","journal-title":"Drugs."},{"key":"497_CR12","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.intimp.2017.10.027","volume":"53","author":"S Tavakolpour","year":"2017","unstructured":"Tavakolpour S. Current and future treatment options for pemphigus: is it time to move towards more effective treatments? Int Immunopharmacol. 2017;53:133\u201342.","journal-title":"Int Immunopharmacol"},{"key":"497_CR13","doi-asserted-by":"crossref","unstructured":"Rosenblum MD, Gratz IK, Paw JS, et al. Treating human autoimmunity: current practice and future prospects. Sci Transl Med. 2012;4(125):125sr1.","DOI":"10.1126\/scitranslmed.3003504"},{"key":"497_CR14","unstructured":"Biogen Inc., Genentech Inc. Rituxan\u00ae (Rituximab) US Prescribing Information [updated 01\/2019]. 1997. https:\/\/www.gene.com. Accessed 1 Aug 2019."},{"key":"497_CR15","unstructured":"European Medicines Agency. MabThera\u00ae (Rituximab) Summary of Product Characteristics [updated 08\/02\/2019]. 2009. https:\/\/www.ema.europa.eu. Accessed 1 Aug 2019."},{"key":"497_CR16","first-page":"87","volume":"8","author":"CC Mok","year":"2014","unstructured":"Mok CC. Rituximab for the treatment of rheumatoid arthritis: an update. Drug Des Devel Ther. 2014;8:87\u2013100.","journal-title":"Drug Des Devel Ther."},{"issue":"2","key":"497_CR17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s11926-017-0632-1","volume":"19","author":"RI Hassan","year":"2017","unstructured":"Hassan RI, Gaffo AL. Rituximab in ANCA-associated vasculitis. Curr Rheumatol Rep. 2017;19(2):6.","journal-title":"Curr Rheumatol Rep."},{"issue":"1","key":"497_CR18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1080\/21678707.2017.1269647","volume":"5","author":"S Shetty","year":"2017","unstructured":"Shetty S, Ahmed AR. Rituximab in the treatment of Pemphigus. Expert Opin Orphan Drugs. 2017;5(1):99\u2013109.","journal-title":"Expert Opin Orphan Drugs."},{"key":"497_CR19","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.intimp.2017.11.005","volume":"54","author":"S Tavakolpour","year":"2018","unstructured":"Tavakolpour S, Mahmoudi H, Balighi K, et al. Sixteen-year history of Rituximab therapy for 1085 Pemphigus vulgaris patients: a systematic review. Int Immunopharmacol. 2018;54:131\u20138.","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"497_CR20","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.autrev.2014.12.002","volume":"14","author":"AR Ahmed","year":"2015","unstructured":"Ahmed AR, Shetty S. A comprehensive analysis of treatment outcomes in patients with Pemphigus vulgaris treated with Rituximab. Autoimmun Rev. 2015;14(4):323\u201331.","journal-title":"Autoimmun Rev"},{"key":"497_CR21","doi-asserted-by":"crossref","unstructured":"Wang HH, W, Li YC, et al. Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens. Acta Derm Venereol. 2015;95(8):928\u201332.","DOI":"10.2340\/00015555-2116"},{"key":"497_CR22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.intimp.2016.02.013","volume":"34","author":"AR Ahmed","year":"2016","unstructured":"Ahmed AR, Nguyen T, Kaveri S, et al. First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: preliminary retrospective study with a seven year follow-up. Int Immunopharmacol. 2016;34:25\u201331.","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"497_CR23","doi-asserted-by":"publisher","first-page":"472","DOI":"10.2340\/00015555-1746","volume":"94","author":"YT Cho","year":"2014","unstructured":"Cho YT, Lee FY, Chu CY, et al. First-line combination therapy with rituximab and corticosteroids is effective and safe for pemphigus. Acta Derm Venereol. 2014;94(4):472\u20133.","journal-title":"Acta Derm Venereol"},{"issue":"9","key":"497_CR24","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1001\/archdermatol.2012.1522","volume":"148","author":"L Lunardon","year":"2012","unstructured":"Lunardon L, Tsai KJ, Propert KJ, et al. Adjuvant Rituximab therapy of Pemphigus: a single-center experience with 31 patients. Arch Dermatol. 2012;148(9):1031\u20136.","journal-title":"Arch Dermatol"},{"issue":"5","key":"497_CR25","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa067752","volume":"357","author":"P Joly","year":"2007","unstructured":"Joly P, Monquet H, Roujeau J-C, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med. 2007;357(5):545\u201352.","journal-title":"N Engl J Med"},{"issue":"10083","key":"497_CR26","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","volume":"389","author":"P Joly","year":"2017","unstructured":"Joly P, Maho-Vaillant M, Prost-Squarcioni C, et al. First-line Rituximab combined with short-term Prednisone versus Prednisone alone for the treatment of Pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017;389(10083):2031\u201340.","journal-title":"Lancet"},{"key":"497_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18482","author":"DM Chen","year":"2019","unstructured":"Chen DM, Odueyungbo A, Csinady E, et al. Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect. Br J Dermatol. 2019. https:\/\/doi.org\/10.1111\/bjd.18482.","journal-title":"Br J Dermatol."},{"key":"497_CR28","unstructured":"European Medicines Agency. MabThera: European public assessment report (EPAR). 2019. https:\/\/www.ema.europa.eu. Accessed 1 Aug 2019."},{"key":"497_CR29","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.intimp.2019.02.037","volume":"71","author":"H Mahmoudi","year":"2019","unstructured":"Mahmoudi H, Balighi K, Tavakolpour S, et al. Unexpected worsening of Pemphigus vulgaris after Rituximab: a report of three cases. Int Immunopharmacol. 2019;71:40\u20132.","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"497_CR30","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1111\/bjd.13823","volume":"173","author":"RJ Feldman","year":"2015","unstructured":"Feldman RJ. Paradoxical worsening of Pemphigus vulgaris following Rituximab therapy. Br J Dermatol. 2015;173(3):858\u20139.","journal-title":"Br J Dermatol"},{"issue":"4","key":"497_CR31","doi-asserted-by":"publisher","first-page":"389","DOI":"10.4103\/0378-6323.174379","volume":"82","author":"VK Sharma","year":"2016","unstructured":"Sharma VK, Bhari N, Gupta S, et al. Clinical efficacy of rituximab in the treatment of pemphigus: a retrospective study. Indian J Dermatol Venereol Leprol. 2016;82(4):389\u201394.","journal-title":"Indian J Dermatol Venereol Leprol."},{"issue":"1","key":"497_CR32","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s13317-017-0100-y","volume":"8","author":"F Du Huynh","year":"2017","unstructured":"Du Huynh F, Mills EA, Mao-Draayer Y. Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment. Autoimmunity Highlights. 2017;8(1):12.","journal-title":"Autoimmunity Highlights."},{"key":"497_CR33","unstructured":"Mignard C, Maho-Vaillant M, Prost-Squarcioni C, et al. Prognostic factors for long-term relapse in patients with pemphigus treated with rituximab in the first line [abstract no. CO 087]. Ann Dermatol Venereol. 2019;146(12 Suppl):A96\u20137."},{"key":"497_CR34","doi-asserted-by":"crossref","unstructured":"Colliou N, Picard D, Caillot F, et al. Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response. Sci Transl Med. 2013;5(175):175ra30.","DOI":"10.1126\/scitranslmed.3005166"},{"issue":"4","key":"497_CR35","doi-asserted-by":"publisher","first-page":"131","DOI":"10.18773\/austprescr.2016.053","volume":"39","author":"KL Randall","year":"2016","unstructured":"Randall KL. Rituximab in autoimmune diseases. Aust Prescr. 2016;39(4):131\u20134.","journal-title":"Aust Prescr."},{"issue":"5","key":"497_CR36","doi-asserted-by":"publisher","first-page":"422","DOI":"10.4103\/0378-6323.140301","volume":"80","author":"AJ Kanwar","year":"2014","unstructured":"Kanwar AJ, Vinay K, Heelan K, et al. Use of rituximab in pemphigus patients with chronic viral hepatitis: report of three cases. Indian J Dermatol Venereol Leprol. 2014;80(5):422\u20136.","journal-title":"Indian J Dermatol Venereol Leprol."},{"key":"497_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.02.021","author":"DF Murrell","year":"2018","unstructured":"Murrell DF, Pena S, Joly P, et al. Diagnosis and management of pemphigus: recommendations by an international panel of experts. J Am Acad Dermatol. 2018. https:\/\/doi.org\/10.1016\/j.jaad.2018.02.021.","journal-title":"J Am Acad Dermatol."},{"issue":"6","key":"497_CR38","doi-asserted-by":"crossref","first-page":"367","DOI":"10.4103\/idoj.IDOJ_290_18","volume":"9","author":"K Vinay","year":"2018","unstructured":"Vinay K, Dogra S. Rituximab in pemphigus: road covered and challenges ahead. Indian Dermatol Online J. 2018;9(6):367\u201372.","journal-title":"Indian Dermatol Online J."},{"issue":"6","key":"497_CR39","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.jaad.2017.07.012","volume":"77","author":"LN Albers","year":"2017","unstructured":"Albers LN, Liu Y, Bo N, et al. Developing biomarkers for predicting clinical relapse in pemphigus patients treated with rituximab. J Am Acad Dermatol. 2017;77(6):1074\u201382.","journal-title":"J Am Acad Dermatol"},{"key":"497_CR40","doi-asserted-by":"crossref","unstructured":"Mignard C, H\u00e9bert V, Maho-Vaillant M, et al. Facteurs de risque de rechute pr\u00e9coce chez les patients atteints de pemphigus trait\u00e9s par rituximab en premi\u00e8re ligne [abstract no. CO 006] [Article in French]. Ann Derm Venerol. 2018;145(12 Suppl):S51.","DOI":"10.1016\/j.annder.2018.09.011"},{"issue":"1","key":"497_CR41","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jaad.2018.01.029","volume":"79","author":"MA Saleh","year":"2018","unstructured":"Saleh MA. A prospective study comparing patients with early and late relapsing Pemphigus treated with Rituximab. J Am Acad Dermatol. 2018;79(1):97\u2013103.","journal-title":"J Am Acad Dermatol"},{"key":"497_CR42","unstructured":"Werth PW, Joly P, Mimouni D, et al. A phase III, randomized, double-blind, controlled study (PEMPHIX) to evaluate the efficacy and safety of rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris [late-breaking abstract]. In: 20th EADV Congress, 2019."},{"key":"497_CR43","unstructured":"F. Hoffmann-La Roche Ltd. Phase III PEMPHIX study shows Roche\u2019s Mabthera\/Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris [media release]. 2019. https:\/\/www.roche.com. Accessed 14 Oct 2019."},{"key":"497_CR44","doi-asserted-by":"publisher","unstructured":"H\u00e9bert V, Vermeulin T, Tanguy L, et al. Comparison of real costs in the French healthcare system in newly diagnosed pemphigus patients: first-line treatment with rituximab versus standard corticosteroid regimen. Data of a national multicentre trial. Br J Pharmacol. 2019. https:\/\/doi.org\/10.1111\/bjd.18563.","DOI":"10.1111\/bjd.18563"},{"issue":"5","key":"497_CR45","doi-asserted-by":"publisher","first-page":"333","DOI":"10.2165\/00063030-200721050-00005","volume":"21","author":"JE Frampton","year":"2007","unstructured":"Frampton JE, Scott LJ. Rituximab: in rheumatoid arthritis. BioDrugs. 2007;21(5):333\u201341.","journal-title":"BioDrugs."},{"key":"497_CR46","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1177\/0091270005277075","volume":"45","author":"CM Ng","year":"2005","unstructured":"Ng CM, Bruno R, Combs D, et al. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol. 2005;45:792\u2013801.","journal-title":"J Clin Pharmacol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-019-00497-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-019-00497-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-019-00497-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T09:56:29Z","timestamp":1659088589000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-019-00497-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,14]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["497"],"URL":"https:\/\/doi.org\/10.1007\/s40257-019-00497-9","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,14]]},"assertion":[{"value":"14 December 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"James Frampton is a salaried employee of Adis International Ltd\/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}